MedPath

A study on efficacy of Ardraka Arka along with standard care in the management of Bronchial Asthma(Tamaka shwasa)

Phase 2
Conditions
Health Condition 1: J452- Mild intermittent asthmaHealth Condition 2: J453- Mild persistent asthmaHealth Condition 3: J453- Mild persistent asthma
Registration Number
CTRI/2023/08/056522
Lead Sponsor
DrPuja MS
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Subjects who are known cases of Bronchial Asthma /Tamaka Shwasa and

are already on the treatment of modern medications.

2. Subjects of age group 6-15 years irrespective of gender, religion, caste and

socio-economic status.

3. Subjects having clinical symptoms of Tamaka Shwasa/ Bronchial Asthma:

4. Subjects falling under the mild persistent, mild intermittent and moderate

persistent types of bronchial asthma as per Nelson.

Exclusion Criteria

1.Subjects admitted to the hospital due to Asthma exacerbation within 4

weeks prior to the visit.

2.Any known uncontrolled systemic disease.

3.Severe persistent type of asthma will be excluded.

4.Patients with a history of any other diagnosed lung pathology.

5.Subjects incompatible for Spirometry evaluation.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To evaluate and compare the effect of Ardraka Arka as an Add-on therapy <br/ ><br>along with standard care on the subjective parameters of Tamaka ShwasaTimepoint: 84 days
Secondary Outcome Measures
NameTimeMethod
To evaluate & compare the changes in spirometry values before & after <br/ ><br>treatment of Ardraka Arka along with the Standard care in Tamaka Shwasa.Timepoint: 84 days
© Copyright 2025. All Rights Reserved by MedPath